Abstract: Methods and compositions for selectively inactivating viruses in biological compositions, including contacting the composition with an organic solvent and an ethyleneimine oligomer inactivating agent, are disclosed.

Abstract: Methods and compositions for selectively modifying nucleic acid molecules in biological compositions, including contacting the composition with an inactivating agent having the formula: 1

Abstract: This invention provides means and methods of inactivating viruses and other organisms in cell-containing or biopolymer-containing compositions without significant alteration of proteins or other biopolymers by contacting such compositions with selective ethyleneimine oligomer inactivating agents, such as the trimer or tetramer.

Abstract: Methods and compositions for selectively modifying nucleic acid molecules in biological compositions, including contacting the composition with an inactivating agent having the formula: 1

Abstract: Methods and compositions for selectively modifying nucleic acid molecules in biological compositions, including contacting the composition with an inactivating agent having the formula: where each of R1, R2, R3, R4, R6, R7, and R8 is, independently, H or a monovalent hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive, provided that R1, R2, R3, R4, R6, R7, and R8 cannot all be H; R5 is a divalent hydrocarbon moiety containing between 2 and 4 carbon atoms, inclusive; X is a pharmaceutically acceptable counter-ion; and n is an integer between 2 and 10, inclusive are disclosed.

Abstract: The present invention provides methods for treating rhinoviral infections in a subject in need of such treatment, by the administration of 2′-5′ oligoadenylates or the analogs thereof. Pharmaceutical formulations comprising 2′-5′ oligoadenylates and analogs thereof are also provided.

Abstract: Methods and compositions for selectively inactivating viruses in biological compositions, including contacting the composition with an organic solvent and an ethyleneimine oligomer inactivating agent, are disclosed.

Abstract: Methods and compositions for selectively modifying nucleic acid molecules in biological compositions, including contacting the composition with an inactivating agent having the formula: where each of R1, R2, R3, R4, R6, R7, and R8 is, independently, H or a monovalent hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive, provided that R1, R2, R3, R4, R6, R7, and R8 cannot all be H; R5 is a divalent hydrocarbon moiety containing between 2 and 4 carbon atoms, inclusive; X is a pharmaceutically acceptable counter-ion; and n is an integer between 2 and 10, inclusive are disclosed.

Abstract: This invention provides means and methods of inactivating viruses and other organisms in cell-containing or biopolymer-containing compositions without significant alteration of proteins or other biopolymers by contacting such compositions with selective ethyleneimine oligomer inactivating agents, such as the trimer or tetramer.

Abstract: The means and methods of inactivating viruses and other organisms in cell-containing or biopolymer-containing compositions comprising contacting such compositions with selective ethyleneimine oligomer inactivating agents are disclosed. The means and methods of this invention selectively modify functional nucleic acids in a cell-containing or biopolymer-containing composition using selective ethyleneimine oligomer inactivating agents, such as the trimer or tetramer without significant alteration of proteins or other biopolymers.

Abstract: Methods and compositions for selectively modifying nucleic acid molecules in biological compositions, including contacting the composition with an inactivating agent having the formula: ##STR1## where each of R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.6, R.sub.7, and R.sub.8 is, independently, H or a monovalent hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive, provided that R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.6, R.sub.7, and R.sub.8 cannot all be H; R.sub.5 is a divalent hydrocarbon moiety containing between 2 and 4 carbon atoms, inclusive; X is a pharmaceutically acceptable counter-ion; and n is an integer between 1 and 10, inclusive are disclosed.

Abstract: A method for treating diseases and symptoms caused by papillomaviruses is presented. The method comprises administering an effective amount of one or more 2',5'-oligoadenylates consisting of the structure: ##STR1## wherein R.sub.2 is PO.sub.4.sup.2- and R.sub.3 is OH, R.sub.2 and R.sub.3 are OH; and n=1 or n=2.

Abstract: The present invention provides methods for treating herpes infections in a subject in need of such treatment, by the administration of 2'-5' oligoadenylate-2',3'-cyclophosphate compounds. Pharmaceutical formulations comprising 2'-5' oligoadenylate-2',3'-cyclophosphate and compounds thereof are also provided.

Abstract: The present invention concerns a method for inactivating a virus for use in e.g. a vaccine, by treating the virus with an ethyleneimine at a pH of less than 7.0, and methods of treatment with the inactivated virus.

Abstract: An enzymatic synthesis is disclosed for papillomavirus inhibitors which are 2',5'-oligoadenylate-2',3'-cyclophosphates having the formula ##STR1## in which 0.ltoreq.n.ltoreq.10, in particular from .gtoreq.0 to 10, preferably 1 or 2. Pharmaceuticals which contain these compounds as the active ingredient, and their use to treat diseases caused by papillomaviruses are also discussed.